Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 212

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 212
---
 to
operate and develop our business, we could be required to seek additional financing earlier than we expect, which may not be
available when needed or at all, or be forced to delay, scale back or eliminate some or all of our proposed operations.

 21 

If we do not successfully identify and acquire
rights to new products and drug candidates and successfully integrate them into our operations, our growth opportunities may be limited.

We plan to pursue the development
of new FDA approved products and drug candidates which may include continued activities to develop and commercialize current assets or,
if and as opportunities arise, potential acquisitions of new intellectual property rights and assets. We have historically relied, and
we expect to continue to rely, primarily upon third parties to provide us with additional development opportunities. We may seek to enter
into acquisition agreements or licensing arrangements to obtain rights to develop new formulations and FDA approved products in the future,
but only if we are able to identify attractive products and formulations and negotiate acquisition or license agreements on terms acceptable
to us, which we may not be able to do. Moreover, we have limited resources to acquire additional potential product development assets
and integrate them into our business. Acquisition opportunities may involve competition among several potential purchasers, which could
include large multi-national pharmaceutical companies and other competitors that have access to greater financial resources than we do.
If we are unable to obtain rights to development and commercial opportunities from third parties and we are unable to rely upon our compounding
pharmacies and current and future relationships with pharmacists, physicians and other inventors to provide us with additional development
opportunities, our growth and prospects could be limited.

Our product development strategy
is to focus on ophthalmology and eye care related products and formulations for which we believe there is broad market potential, large
unmet needs and/or unique value to physicians and patients and to develop and offer formulations and products within these therapeutic
areas that could afford us with gross and operating margins consistent with our current and historical figures. However, our expectations
and assumptions about market potential and patient needs may prove to be wrong, and we may invest capital and other resources on products,
drug candidates, and formulations that do not generate sufficient revenues for us to recoup our investment.

We may be unable to successfully develop and
commercialize our drug products, candidates or any other assets we may acquire. 

We have acquired assets related
to drug products and drug candidates. We are currently pursuing development and commercialization opportunities with respect to a number
of these products and